{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:19:23Z","timestamp":1787829563456,"version":"build-2784847793"},"reference-count":125,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2026,8,3]]},"DOI":"10.1080\/13543784.2026.2710840","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:59:50Z","timestamp":1785326390000},"page":"581-589","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Investigational IL-17A antagonist in the treatment of psoriatic arthritis - a review"],"prefix":"10.1080","volume":"35","author":[{"given":"Osariemen","family":"Osunbor","sequence":"first","affiliation":[{"name":"Barnsley Hospital NHS Foundation Trust","place":["South Yorkshire, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Ren\u00e9","family":"Nkeck","sequence":"additional","affiliation":[{"name":"University of Yaound\u00e9 I","place":["Yaound\u00e9, Cameroon"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7368-7083","authenticated-orcid":false,"given":"Adewale O.","family":"Adebajo","sequence":"additional","affiliation":[{"name":"Barnsley Hospital NHS Foundation Trust","place":["South Yorkshire, UK"]},{"name":"University of Sheffield","place":["South Yorkshire, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30830-4"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.027"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.07.001"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker216"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103889"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X241274537"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01346-6"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2009.12.001"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-016-0029-z"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X241295920"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205675"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22926"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X21998279"},{"key":"e_1_3_5_18_1","volume-title":"Donner un sens \u00e0 l\u2019intelligence artificielle: Pour une strat\u00e9gie nationale et europ\u00e9enne","author":"Villani C","year":"2018","unstructured":"Villani C, Schoenauer M, Bonnet Y, et al. Donner un sens \u00e0 l\u2019intelligence artificielle: Pour une strat\u00e9gie nationale et europ\u00e9enne. Paris: Mission parlementaire; 2018. [Giving Meaning to Artificial Intelligence: For a National and European Strategy. Paris: Parliamentary Mission; 2018]."},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204858"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1468252"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.12.003"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-0165-3"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211734"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23249"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40726"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez383"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1810-5"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17-1-65"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-014-0097-1"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150614"},{"issue":"1","key":"e_1_3_5_32_1","first-page":"CD012722","article-title":"Methotrexate for psoriatic arthritis","volume":"1","author":"Wilsdon TD","year":"2019","unstructured":"Wilsdon TD, Whittle SL, Thynne TR, et al. Methotrexate for psoriatic arthritis. Cochrane Database Syst Rev. 2019;1(1):CD012722.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140877"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33161-7"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140647"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22379"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.081430"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216835"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02302-9"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02303-0"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30265-8"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30263-4"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221019"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221048"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000990"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219014"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615977"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022516"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218870"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32483-8"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207963"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150626"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1186\/s43166-022-00128-y"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02693-w"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01687-w"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225534"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37876"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195123"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209131"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212825"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.1012044"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8702-3"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14702"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241575"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/cpu6r9"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez087"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02417-x"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/prd.12083"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31472-1"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.596086"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.01.006"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20192048"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214944"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0175-0"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0091-8"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S105263"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38376"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41239"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.188"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-011-1036-6"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex301"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3908061"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"issue":"8","key":"e_1_3_5_88_1","first-page":"821","article-title":"Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials","volume":"14","author":"Gottlieb AB","year":"2015","unstructured":"Gottlieb AB, Langley RG, Philipp S, et al. Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials. J Drugs Dermatol. 2015;14(8):821\u2013833.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512711"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00125-2"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01620-3"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00440-2"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2025.05.005"},{"issue":"10","key":"e_1_3_5_96_1","first-page":"1450","article-title":"Sonelokimab demonstrates superior tissue penetration and enthesitis resolution in active PsA: primary results from the phase 3 VELA program","volume":"77","author":"Mease PJ","year":"2025","unstructured":"Mease PJ, Merola JF, Kristensen LE, et al. Sonelokimab demonstrates superior tissue penetration and enthesitis resolution in active PsA: primary results from the phase 3 VELA program. Arthritis Rheumatol. 2025;77(Suppl 10):1450.","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26188794"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-025-00754-w"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2025.2500292"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2024-eular.1295"},{"issue":"5","key":"e_1_3_5_101_1","first-page":"1374","article-title":"Sonelokimab, a novel IL-17A\/F-inhibiting nanobody, in patients with active psoriatic arthritis: a randomized, placebo-controlled, phase 2 trial","volume":"30","author":"McInnes IB","year":"2024","unstructured":"McInnes IB, Coates LC, Mease PJ, et al. Sonelokimab, a novel IL-17A\/F-inhibiting nanobody, in patients with active psoriatic arthritis: a randomized, placebo-controlled, phase 2 trial. Nat Med. 2024;30(5):1374\u20131382.","journal-title":"Nat Med"},{"issue":"25","key":"e_1_3_5_102_1","first-page":"00815","article-title":"Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"0003","author":"Taylor PC","year":"2025","unstructured":"Taylor PC, Mease PJ, de Vlam K, et al. Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Ann Rheum Dis. 2025;S0003-4967(25):00815\u20135.","journal-title":"Ann Rheum Dis"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.536"},{"key":"e_1_3_5_104_1","unstructured":"ACELYRIN Inc. A phase 2b pivotal study to evaluate the efficacy and safety of izokibep in subjects with non-infectious intermediate- posterior- or pan-uveitis [Internet]. Bethesda (MD): National Library of Medicine (US); 2025 Feb [cited 2025 Dec 9]. Identifier: NCT05384249."},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2017.04.007"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2024.2337749"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00928-w"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2024-eular.LBA85"},{"issue":"10","key":"e_1_3_5_109_1","first-page":"L05","article-title":"Efficacy and safety of DC-853, a novel oral IL-17 antagonist, in moderate-to-severe psoriasis and psoriatic arthritis: phase 2b results","volume":"77","author":"Blauvelt A","year":"2025","unstructured":"Blauvelt A, Warren RB, Ghoreschi K, et al. Efficacy and safety of DC-853, a novel oral IL-17 antagonist, in moderate-to-severe psoriasis and psoriatic arthritis: phase 2b results. Arthritis Rheumatol. 2025;77(Suppl 10):L05.","journal-title":"Arthritis Rheumatol"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00422"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.4c00469"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16010111"},{"key":"e_1_3_5_113_1","unstructured":"Pharmaceutical Technology. SAR-441566 by sanofi for rheumatoid arthritis: likelihood of approval [Internet]. London: Verdict Media; 2023 [cited 2025 Dec 9]. Available from: https:\/\/www.pharmaceutical-technology.com\/data-insights\/sar-441566-sanofi-rheumatoid-arthritis-likelihood-of-approval\/"},{"key":"e_1_3_5_114_1","unstructured":"Sanofi. A phase 2 international multicenter randomized double-blind placebo-controlled dose-ranging study of efficacy and safety of SAR441566 in adults with moderate to severe plaque psoriasis [Internet]. Bethesda (MD): National Library of Medicine (US); 2025 Oct [cited 2025 Dec 9]. Identifier: NCT06073119. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06073119"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2024-5-6"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2560505"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.01.005"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2025.2558829"},{"issue":"1","key":"e_1_3_5_119_1","article-title":"Efficacy and safety of AK111 in patients with active ankylosing spondylitis: results from a randomized, double-blind, placebo-controlled, phase II clinical study","volume":"210","author":"Li Z","year":"2023","unstructured":"Li Z, Xia Y, Wang M, et al. Efficacy and safety of AK111 in patients with active ankylosing spondylitis: results from a randomized, double-blind, placebo-controlled, phase II clinical study. J Immunol. 2023;210(1 Suppl):165.18.","journal-title":"J Immunol"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01450-x"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.14412\/1996-7012-2024-4-33-42"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.14412\/1996-7012-2024-1-35-46"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00554-4"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000045259"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1624463"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.1177\/20417314221085390"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2026.2710840","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13543784.2026.2710840","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2026.2710840","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:31:49Z","timestamp":1787826709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2026.2710840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":125,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,3]]}},"alternative-id":["10.1080\/13543784.2026.2710840"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2026.2710840","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}